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For men in the United States, prostate cancer (PCa) is the
most frequentmalignancyand the second leading causeof
cancer mortality. The metastatic spread of PCa is respon-
sible for most deaths related to PCa. AlthoughKISS1 func-
tions as a metastasis suppressor in various cancers, its
expression levels and functions in PCa development and
progression remain undetermined. The goals of this study
were to correlate the expression levels of KISS1 in PCas
with clinicopathologic characteristics and to assess the
biological relevanceofKISS1 to theviability andmotilityof
PCa cells. Strong KISS1 staining was detected in benign
prostate tissues, but the staining was weaker in primary
and metastatic PCas (both P< 0.001, t-test). Furthermore,
the low expression levels of KISS1 in PCas correlated with
clinical stage (P< 0.01) and with KISS1R expression (P<
0.001). Overexpression of full-length KISS1 in low
KISS1-expressing PC-3M cells, but not KFMSS,
which lacks the secretion signal sequence, induced
re-sensitization of cells to anoikis, although it had
no effect on either cell proliferation or apoptosis.
Overexpression of KISS1 also suppressed steps in
the metastatic cascade, including motility and inva-
siveness. Moreover, cells overexpressing KISS1
were found to enhance chemosensitivity to pacli-
taxel. Collectively, our data suggest that KISS1 func-
tions as a metastasis suppressor in PCas and may
serve as a useful biomarker as well as a therapeutic
target for aggressive PCas. (Am J Pathol 2012, 180:
1170–1178; DOI: 10.1016/j.ajpath.2011.11.020)
1170Prostate cancer (PCa) is the most frequent malignancy
and the second leading cause of cancer mortality in men
40 years of age and older. Although early detection and
hormone-based therapies generally result in responses
and reduce mortality, current therapies for advanced or
recurrent PCa are not curative.1 Even patients who have
undergone apparently successful surgical resection may
experience recurrence locally or at distant sites months
or years later.2,3 Metastatic spread is responsible for
most PCa-related deaths. The size and histology of the
primary tumor do not provide a reliable prognosis, be-
cause tumor cells may have already disseminated by the
time PCa is diagnosed.2 Thus, identification and charac-
terization of molecular signatures that provide information
about clinical risk assessment are needed.
Over the past two decades,30 molecules involved in
suppression of metastasis have been recognized.4,5
These inhibit one or more steps of the metastatic cas-
cade, including cell proliferation, apoptosis, epithelial to
mesenchymal transition, adhesion, invasion, angiogene-
sis, and colonization of ectopic tissues. The KISS1 gene
was first identified as a metastasis suppressor for human
melanoma.6 It is differentially up-regulated in C8161 mel-
anoma cells, which had lost the potential to metastasize
after microcell-mediated chromosomal transfer of an in-
tact copy of chromosome 6. Radiation hybrid mapping
and fluorescence in situ hybridization showed that the
KISS1 gene mapped to 1q32 as a single locus.7 The
KISS1 protein can be cleaved and secreted as kisspeptin
(KP54, KP14, KP13, or KP10).8,9 KISS1 binds to an
G protein–coupled receptor, GPR54, now referred to as
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AJP March 2012, Vol. 180, No. 3the KISS1 receptor (KISS1R).10–12 Despite the lack of
KISS1R expression in many tumor cell lines, metastasis is
suppressed by KISS1 re-expression, suggesting that KISS1
signals either through KISS1R or through unidentified, alter-
native signaling pathways.9,13
Levels of KISS1 expression have prognostic relevance
and correlate with invasiveness in several human can-
cers, including renal cell carcinoma and melanoma and
esophageal, bladder, brain, breast, ovarian, and pancre-
atic cancers.14–19 Low or lost KISS1 expression is gen-
erally associated with higher tumor grade, increased
metastatic potential, and a poor prognosis. A function for
KISS1 has been reported in xenograft models, where its
re-expression in melanomas, breast cancers, and pan-
creatic cancers resulted in reduced growth of orthotopic
tumors in breast and pancreatic cancers and metastases
to other organs in all of the tested models.6,13,20 Studies
with human melanomas and breast cancer xenografts
show that KISS1 maintains disseminated tumor cells in a
dormant state, blocks development of macroscopic me-
tastases, and prevents cancer cells from colonizing and
proliferating at secondary sites.9,13,14,20,21 Because dis-
semination of cancer cells may occur before clinical de-
tection of micrometastasis, interventions that target colo-
nization will be valuable for cancer therapy. Although
KISS1 has been implicated in controlling formation of
macroscopic metastases of some cancers, its function as
a suppressor of metastasis for other cancers is not uni-
versal. For example, KISS1 expression was not associated
with tumor size or invasion in esophageal squamous cell
carcinoma, but it was a significant predictor of lymph node
metastasis.17 In hepatocellular carcinoma and breast can-
cers, increased KISS1 levels are associated with disease
progression or a worse clinical outcome.18,22,23
In this report, we show that KISS1 expression is down-
regulated in PCas and correlates with clinical stage and
with expression of KISS1R. Furthermore, loss of KISS1
expression correlates with enhanced metastatic capacity
of commonly used PCa cell lines; stable overexpression
of KISS1 induces anoikis, increased chemosensitivity,
and decreased cell migration and invasion. These results
indicate that loss of KISS1 expression in PCas is associ-
ated with increased cancer progression and that KISS1
regulates steps that are involved in cell metastasis.
Materials and Methods
Cells
DU-145, MDA-PC-2b, PC-3, and PC-3M cells were cul-
tured in T-medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (HyClone Laborato-
ries, Inc., Logan, UT) in a 37°C, 5% CO2 incubator.
Wound-Healing Cell Migration Assay
Cell migration assays were performed as previously de-
scribed. Briefly, cells (2  105) were seeded in 6-well
plates, and cells were allowed to form an 80% confluent
monolayer in a six-well plate and then cultured in serum-
free medium overnight before wounding. The wound wasmade by the tip of a 200-L micropipette passed across
the monolayer. Cell migration was induced by adding
serum-free medium supplemented with 10 ng/mL epi-
dermal growth factor. After 24 or 48 hours, the distance
that cells moved was determined and quantified in
Metamorph imaging software. Shown are the mean
values  SEMs of six measurements for each time
point and condition. All measurements were normal-
ized to 0-hour controls.
Invasion Assays
Cancer cell invasiveness was determined with a 24-well
Transwell plate (8-m pore polycarbonate membrane in-
serts; Corning Inc., Corning, NY) according to the man-
ufacturer’s protocol. For these assays, 5 104 cells were
plated in the Matrigel-coated chamber inserts. Cells were
suspended in medium without serum or growth factors,
and medium with 10 ng/mL epidermal growth factor was
used as a chemoattractant in the lower chamber. After
incubation at 37°C for 18 hours, the noninvasive cells on
the top chambers were gently removed with cotton
swabs. The invading cells on the underside of the mem-
brane were fixed in 100% methanol for 10 minutes, air-
dried, stained in 0.1% crystal violet, and counted under
a microscope. The numbers of invaded cells in five
random, 10 microscopic fields were counted and
expressed as percentages of the control. The results
shown represent mean  SD of invading cells from
three independent experiments, each accomplished in
triplicates.
Tissue Specimens
PCa tissue microarrays were from commercially available
suppliers (US Biomax, Inc., Rockville, MD; PR954 and
PR2085a) and those developed by the University of Ala-
bama at Birmingham Cancer Program Tissue Core. In-
cluded were 35 normal/benign prostatic hyperplasia
(BPH) tissues, 210 prostate primary cancers, and 8 met-
astatic tumors. The use of all tissues was approved by the
Institutional Review Boards of Tuskegee University and
the University of Alabama at Birmingham. All specimens
were subjected to immunohistochemical (IHC) analysis in
parallel and processed simultaneously with an identical
protocol. Clinicohistopathologic characteristics of the
subjects in the tissue microarray study included age at
surgery, grade, clinical stage, and Gleason score ac-
cording to information provided by the suppliers. The
expression levels were classified as negative (0.3),
weak positive (0.3 to 1.5), or strong positive (1.5).
IHC Staining
Tissues were de-paraffinized in xylene and rehydrated in
graded alcohols. For antigen retrieval of KISS1 and
KISS1R, the slides were pressure-cooked for 10 minutes.
Endogenous peroxidase activity was quenched with 3%
hydrogen peroxide for 5 minutes. Slides were blocked by
3% goat serum at room temperature for 1 hour in humidity
chambers with KISS1 or KISS1R antibody. Mass spec-
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was a gift from Dr. Danny Welch (University of Kansas).
Rabbit anti-human KISS1R (375 to 398) polyclonal an-
tibody was from Phoenix Pharmaceuticals Inc. (Burlin-
game, CA). The biotinylated goat anti-mouse secondary
antibody and the avidin/horseradish peroxidase label
were each applied for 10 minutes (BioGenex Laborato-
ries, Inc., Fremont, CA). The antigen-antibody reaction
was visualized after diaminobenzidine was applied for 7
minutes. The slides were counterstained with hematoxylin
for 1 minute. Positive controls were included in each
staining run; negative controls were obtained by omitting
the primary antibody. Slides were then dehydrated in
alcohols and cleared in three xylene baths before being
mounted with Permount media. As reported earlier,24
these antigens are stable in paraffin blocks.
Generation of PC-3M Cell Lines Stably
Expressing KISS1 (KFM) or KISS1SS
(KFMSS)
PC-3M cells were transfected with pcDNA3.1 constructs
(pcDNA3.1 vector control; the KFM construct contains
full-length KISS1 and FLAG tag; KFMSS lacks the se-
cretion signal sequence) with the use of Lipofectamine
2000 (Invitrogen). DNA-containing medium was removed
and replaced with T-medium. KISS1-overexpressing
cells were selected by incubation in medium containing
400 g/mL G418 (selective for eukaryotic cells) and 2.5
g/mL puromycin for 14 days.
RNA Extraction and Quantitative Real-Time PCR
Total RNA was isolated with Trizol (Invitrogen) according
to the manufacturer’s protocol. For quantification, cDNA
was synthesized with 1 g of RNA in a reverse transcrip-
tion reaction with random hexamers and oligo-dT primer
in an unbiased manner (SABiosciences, Frederick, MD).
cDNA was amplified with the SYBR Green qPCR Master
Mix (SABiosciences) with a real-time PCR Applied Bio-
systems 7500 fast thermocycler (Applied Biosystems
Inc., Foster City, CA). The expression of mRNAs (KISS1
and KISS1R) was determined with manufacturer-sup-
plied RT2 qPCR Primer Assays (SABiosciences). The
mRNA expression levels were normalized to GAPDH or
-actin housekeeping genes. Experiments were per-
formed in triplicate.
Western Blot Analyses
Approximately 5  106 cells were lysed in RIPA buffer
with a proteinase inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO), and the total protein concentrations were
determined with the bicinchoninic acid assay (Pierce,
Rockford, IL). Protein (30 to 50 g) was loaded onto
10% SDS-PAGE gels. Antibodies used for Western blot
or IHC analyses included polyclonal anti-actin anti-
body (Sigma-Aldrich; 1:5000), anti-KISS1 antibody
(provided by Dr. Welch, University of Alabama at Bir-
mingham; 1:400), and horseradish peroxidase-conju-gated anti-rabbit or anti-mouse secondary antibodies
(enhanced chemiluminescence-horseradish peroxi-
dase linked secondary antibodies, 1:5000; Amersham
Biosciences, Buckinghamshire, UK). Each experiment
was performed in triplicate.
Cell Proliferation Assay and Chemosensitivity
Assay
Cell growth was determined by the cell proliferation re-
agent WST-1 (water soluble tetrazolium salt-1; Roche,
Mannheim, Germany). Briefly, 2.5  103 cells were
seeded into 96-well plates in quadruplicate for each con-
dition. At 24, 48, and 72 hours, WST reagent was added
to each well at a 1:10 dilution, and the preparations were
incubated for another 2 hours. Sample absorbance was
measured at 560 nm/495 nm. Each experiment was per-
formed in triplicate.
For chemosensitivity assay, the cells were cultured for
the indicated number of days and exposed to paclitaxel
at the concentrations indicated. The proliferation rates of
cells were measured by the WST-1 assay.
Anchorage-Independent Growth (Soft Agar)
Assay
Noble agar (1.5 mL of 0.6%) in growth medium was
solidified in six-well plates. Cells (1  104) per well were
plated in triplicate in 0.3% agar onto the bottom agar. The
cells were incubated at 37°C in a 5% CO2 incubator for
15 days. Fresh growth medium (0.5 mL/well) was added
after 1 week. At the end of incubation, colonies were
stained with 0.005% crystal violet for 1 hour and photo-
graphed.
Anoikis Assay
For assay of anoikis, cells were cultured in complete
medium on an ultra-low attachment six-well plate (1 
106 per well; Corning Inc., Corning, NY). The growth rate
and viability of cells cultured in suspension were mea-
sured by the trypan blue exclusion assay.
Statistical Analyses
All data presented as means  SDs were analyzed with
Prism software version 5.0 (GraphPad, La Jolla, CA) or
Matlab version 7.9 software (Mathworks, Natick, MA). The
significance of the observed differences was determined
with the Student’s t-test, the 2 test, or Fisher’s exact test.
Fisher’s exact test is performed when one or more cells
with expected values is 5. P  0.05 was considered
significant.
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Clinical Significance of KISS1 and KISS1R
Expression in Noncancerous Prostate and
PCa Tissues
To determine the clinical significance of KISS1 and
KISS1R in human PCas, analysis of their expression was
Table 1. Clinicopathologic Characteristics of the Cohort (n  253)
Parameter n (%)
Age
28 to 50 years 11 (4.4)
51 to 60 years 29 (11.5)
61 to 70 years 120 (47.4)
71 to 88 years 93 (36.7)
Clinical stage
1 0 (0.0)
2 7 (15.9)
3 24 (54.5)
4 13 (29.6)
Gleason score
6 35 (25.5)
7 26 (19)
8 76 (55.5)
Gleason score or clinical stage may not be available in some cases.
Therefore, the total number of patients varies.conducted by IHC staining. Tissue microarrays, derived
from 253 samples of prostate tissues from patients with
BPH, uninvolved normal prostate, and PCa (as described
in Tissue Specimens) were evaluated for expression of
KISS1 and KISS1R. The clinicopathologic characteristics
of the cohort are described in Table 1. Benign (BPH or
uninvolved normal prostate tissues) human prostate cells
showed intense KISS1 expression in both the cytoplas-
mic and nuclear compartments (Figure 1A). Primary tu-
mors showed decreased KISS1 staining and a pattern of
progressively reduced KISS1 levels with increasing tu-
mor grades (Figure 1, B and C). A lack of KISS1 staining
in metastatic PCa tumors was observed (Figure 1D). The
mean intensity score of KISS1 was 1.34  0.87 in benign
tumors (n 35); primary and metastatic tumors exhibited
a lower expression [the mean intensity scores were
0.35  0.36 in primary PCa tissues (n  210) and 0.21 
0.36 in metastasis tissues (n  8); Figure 1E; both
P values  0.0001]. The expression levels were also
categorized as negative (0.3), weak positive (0.3 to
1.5), or strong positive (1.5). KISS1 expression in pri-
mary PCas (49% negative, 48% weak positive, and 3%
strong positive) and metastatic PCa tissues (77% nega-
tive, 23% weak positive, and 0% strong positive) were
significantly lower relative to BPH tissues (18% negative,
Figure 1. Expression of KISS1 in human non-
cancerous prostate tissues and PCa tissues. Rep-
resentative immunostaining photomicrographs:
Strong immunoreactivity of KISS1 was detected
in control prostate benign tissues (A) and re-
duced staining in low-grade (Grade II) (B) and
high-grade (Grade IV) (C) PCas. The KISS1 pro-
tein was not evident in metastatic PCas (D).
Original magnification, 400. Immunostaining
was accomplished with anti-human KISS1 anti-
body. Scale bar  20 m. E: Compared with
noncancerous prostate tissues, the overall ex-
pression of KISS1 was lower in PCa tissues and
metastatic tissues (both P 0.001). F: Frequency
distribution of KISS1 staining intensity in pros-
tate tissues. The expression levels were classi-
fied as negative (0.3), weak positive (0.3 to
1.5), or strong positive (1.5).
. Theref
ne or m
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Although no significant difference in KISS1 expression
was observed between primary and metastatic tissues,
(P  0.32; Figure 1, E and F), loss of KISS1 expression
positively correlated with clinical stages II/III and IV and
metastatic tumors (P  0.01; Table 2), and the KISS1
expression is significantly lower (P  0.01) in metastatic
tissues than in earlier stage primary PCa (clinical stages
II/III), indicating loss of KISS1 expression correlated
with PCa progression. KISS1R expression was weak
and only mildly positive in normal prostate tissues, and
decreased expression was observed in primary and
metastatic tissues (see Supplemental Figure S1 avail-
able at http://ajp.amjpathol.org). This decrease in
KISS1 expression positively correlated with the de-
crease of KISS1R expression in PCas, as determined
by the 2 test (Table 2).
Re-Expression of KISS1 in Prostate PC-3M Cell
Line
To assess whether KISS1/KISS1R expression is involved
in cancer metastasis, their expression was determined,
by real-time PCR analysis, in a panel of human PCa cell
lines with varying degrees of metastatic capacity (low to
high: DU-145, MDA-PC-2b, PC-3, PC-3M). Decreased
expression of KISS1/KISS1R correlated with the meta-
static propensity of the cell lines, with PC-3M, which is
highly metastatic, exhibiting the lowest expression (see
Supplemental Figure S2 available at http://ajp.amjpathol.
org). Thus, PC-3M cells were selected to determine the
biological significance of re-expressing KISS1.
KISS1-containing constructs with (KFM) or without
(KFMSS) a secretion signal sequence were used (the
pcDNA3.1 vector control; KFM, contains full-length
KISS1; KFMSS lacks the secretion signal construct, as
described previously9). These constructs were trans-
fected into PC-3M-RFP cells. After transfection, neomy-
Table 2. Relation between KISS1 and Clinical Features in Patien
Variable Analyzable cases, n*
Total 218
Age
60 years 34
60 and 70 years 91
70 years 93
Gleason score
6 35
7 26
8 76
Clinical stage
II/III 31
IV 13
Metastatic PCa 8
KISS-1R
Negative 130
Positive 65
*Gleason score or clinical stage may not be available in some cases
†P values were obtained with the 2 test or Fisher’s exact test when ocin- and puromycin-resistant PC-3M clones were se-lected, and KISS1 expression was confirmed by real-
time PCR and Western blot analyses (see Supplemental
Figure S3 available at http://ajp.amjpathol.org). Trans-
fected clones were selected and identified according
to the highest levels of KISS1 expression at the RNA
and protein levels (see Supplemental Figure S3 avail-
able at http://ajp.amjpathol.org). From each transfec-
tion, the clone with the highest KISS1 expression was
selected for experiments focused on factors affecting
metastases.
KISS1 Expression Inhibits Anchorage-
Independent Growth but Not Anchorage-
Dependent Growth of PCa Cells
To determine whether KISS1 expression affects growth of
PCa cells, we used cell proliferation reagent WST-1 to
assay cell proliferation and cell viability of PC-3M KFM
and PC-3M KFMSS stable clones. Overexpression of
KISS1 in PC-3M cells (PC-3M KFM and PC-3M KFMSS)
had no effect on cell growth in monolayer cultures (Figure
2A), even under serum-free conditions (data not shown).
An essential characteristic of metastatic cancer cells is
resistance to anoikis.25,26 This attribute allows the sur-
vival of metastatic cancer cells during systemic circula-
tion and facilitates their metastasis to distant organs.
Therefore, the influence of KISS1 on anoikis in PC-3M
KFM and PC-3M KFMSS cells was determined by mea-
suring cell viability in the absence of matrix attachment.
Under nonadherent conditions (cells cultured in ultra-low
attachment plates), PC-3M KFM cells exhibited a reduc-
tion in cell viability greater than that of PC-3M vector
control cells, as determined by trypan blue viability ex-
periments and crystal violet staining compared with cells
recovered from normal culture plates (Figure 2B). PC-3M
KFMSS cells exhibited almost no difference from vector
control cells. These results indicate that KISS1 expres-
Prostate Cancer
KISS1 score
P†egative, n (%) Positive, n (%)
109 (50.0) 109 (50.0)
16 (47.0) 18 (53) 0.7845
44 (48.4) 47 (51.6)
49 (52.7) 44 (47.3)
15 (42.9) 20 (58.1) 0.3466
12 (46.2) 14 (53.8)
43 (56.6) 33 (43.4)
7 (22.6) 24 (77.4) 0.0035
8 (61.5) 5 (38.5)
6 (75) 2 (25)
80 (61.5) 50 (38.5) 0.0001
21 (32.3) 44 (67.7)
ore, the total number of patients varies.
ore cells had expected values  5.ts with
Nsion and secretion have no effect on cell proliferation but
compared with the vector control (points indicate mean; bars, SD). ***P 
0.001, lower panels.
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age-independent conditions.
In addition, PC-3M KFM cells exhibited either no
change or a slight decrease in total cell number when
cultured in ultra-low attachment plates, whereas the num-
ber of PC-3M vector control cells cultured in suspension
continued to increase (data not shown). To determine
whether KISS1 overexpression affects the anchorage-
independent growth of PC-3M cells, the capacity of
KISS1-expressing cells to form colonies in soft agar was
assessed (Figure 2C). After 15 days of culture, image
analysis showed that vector control cells had formed a
greater number (1.5-fold) of colonies of larger size (1.9-
fold) relative to PC-3M KFM cells (Figure 2C). This indi-
cates that KISS1 expression reduces anchorage-inde-
pendent growth of PCa cells, an essential step for
metastasis.
KISS1 Re-Expression Decreases PCa Cell
Motility and Invasiveness
Because KISS1 functions as a metastasis suppressor,
the effect of its overexpression on cell migration, a feature
necessary for the motility of cancer cells, was tested. The
migration of PC-3M cells was delayed by expression of
KFM (full-length KISS1) but not with KFMSS (Figure 3A),
indicating that KISS1 secretion is required for inhibition of
cancer cell migration. To determine the effect of KISS1
expression on the invasive potential of PC-3M cells, the
invasiveness of KISS1 and vector control clones was
evaluated with Matrigel chambers. Figure 3B shows a
representative image of PC-3M cells stained with crystal
purple on the bottom of a Matrigel-coated membrane. A
greater number of cells transfected with the empty vector
invaded through the Matrigel, relative to those with
PC-3M KFM and KFMSS expression (Figure 3B), indi-
cating that KISS1 expression inhibits invasion and that
KISS1 secretion is required for inhibiting of motility.
KISS1 Overexpression Enhances
Chemosensitivity of Cancer Cells
Increased susceptibility of cancer cells to chemothera-
peutic agents would represent an important advance-
ment in the treatment of patients with advanced or met-
astatic PCa.27 Therefore, the effect of KISS1 levels on the
chemosensitivity of PCa cells was determined. PCa cells
(PC-3M control, PC-3M KFM, and PC-3M KFMSS) were
exposed for 72 hours to various concentrations (0, 0.1,
0.3, 1, 3, 10, 30 nmol/L) of paclitaxel, a chemotherapeutic
agent commonly used for treatment of PCas. As deter-
mined with the WST-1 assay at 72 hours after exposure,
paclitaxel inhibited cell growth in a dose-dependent man-
ner (Figure 4A). For the PC-3M control and PC-3M
KFMSS cells, 0.1 nmol/L paclitaxel had no effect on
growth, whereas for cells with KISS1 overexpression both
0.1 and 0.3 nmol/L paclitaxel decreased the number of
viable cells. WST-1 assays for cell proliferation were also
conducted on cells (days 1, 3, and 5) receiving 0.1Figure 2. Effect of KISS1 expression on cell proliferation and viability. A:
KISS1 does not affect anchorage-dependent growth of PCa cells. The cells
were cultured for the indicated number of days, and proliferation of
KISS1-expressing cells was measured by the WST-1 assay. B: KISS1 re-
duces cell viability under anchorage-independent conditions compared
with vector controls and KFM and KFMSS expression. At each time
point, cell viability was determined by trypan blue staining. Points indi-
cate mean; bars, SD. **P  0.01, ***P  0.001. Photomicrographs show
representative viable cells from KISS1 and KFMSS-expressing and vector
control, PC-3M cells regrown in normal plates after 96 hours of indepen-
dent culture, stained with crystal violet. C: KISS1 overexpression inhibits
anchorage-independent growth of PCa cells. Photographs show represen-
tative colonies formed from PC-3M vector and PC-3M KFM-transformed
cells grown in soft agar. KISS1 reduced the numbers and sizes of coloniesnmol/L paclitaxel treatment over a 5-day period (Figure
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viable PCa cells relative to PC-3M controls at 72 and 120
hours (Figure 4B). These data indicate that KISS1 over-
expression sensitizes PC-3M cells to the effects of pacli-
taxel.Discussion
KISS1 expression has been measured in clinical sam-
ples, including melanomas and breast, urinary bladder,
and pancreatic cancers, showing its diagnostic and
Figure 3. Effects of KISS1 overexpression on migration and invasion of PC-3M
cells.A:Measurement of cellmigration of stably overexpressingKISS1 cells that used
wound healing assay. PC-3M vector only, PC-3M KFM, and PC-3M KFMSS cells
were wounded and treated with 10 ng/mL epidermal growth factor (EGF) 24 hours.
Red vertical bars indicate starting point on day 0, and yellowvertical bars indicate the
leading edge ofmigrating cells after 24 hours. PC-3M-RFPKFM cells and PC-3MGFP
cells, (middle right panel) were mixed, and migration of denuded area was
measured. PC-3M cells stably expressing KISS1 (RFP; red) migrated slower than
PC-3M cells stably expressing green fluorescent protein (GFP; green; arrow).
Bar graph (bottom) indicates quantification of areamigrated after 24 hours in six
individual experiments  SD. *P  0.01, analyzed by t-test. B: Effects of KISS1
overexpression on invasion by PC-3M cells. Cells that penetrated the Matrigel-
coated membrane were fixed in formaldehyde and stained with crystal violet.
Photos are representative fields of invasive cells on the membrane. Original
magnification, 100. Bar graphs represent the average number of cells on the
underside of the membrane  SD. **P  0.01, ***P  0.001, analyzed by t-test.
Figure 4. The effects of KISS1 overexpression
on chemosensitivity of PCa cells. The prolifera-
tion of PC-3M cells in the presence of paclitaxel
or control was measured by the WST-1. A:
Growth curves of PC-3M vector control, KFM, or
KFMSS cells exposed to increasing concentra-
tions of paclitaxel (0 nmol/L, 0.1 nmol/L, 0.3
nmol/L, 1 nmol/L, 3 nmol/L, or 10 nmol/L) for 72
hours. B: Growth curves of PC-3M vector con-
trol, KFM, or KFMSS cells exposed to 0.1
nmol/L paclitaxel over a 5-day periods. WST-1
assays were conducted at 0, 24, 72, and 120
hours. Data are reported as the percentage of
growing cells compared with vector controls and
represent mean values  SDs of at least three
independent experiments.
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sive evaluation of KISS1 expression in human PCa tis-
sues in a large cohort and evaluates the effect of KISS1
expression on PCa cell lines. As hypothesized, KISS1
was strongly expressed in normal and BPH tissues. In
contrast, decreased expression was observed in early
stage primary tumors, with a progressive loss of expres-
sion in late stage and metastatic tumors. The loss of
KISS1 expression correlated with both advanced clinical
cancer stages and the loss of KISS1R. Although a statis-
tical correlation was not observed, there was an increas-
ing percentage of patients with cancers that were KISS1
negative and a decreasing percentage of patients with
cancers that were KISS1 positive in relation to increasing
Gleason score and tumor grade. Given the significant
inverse correlation between KISS1 expression and clini-
cal stage, measurement of KISS1 expression levels may
be useful for improving the overall risk assessment of
patients with PCa in combination with clinical staging,
Gleason score, and tumor grade.
We have re-expressed full-length KISS1 and have pre-
pared a deletion mutant, KFMSS, which lacks capacity
to be secreted.9 Re-expression of full-length KISS1 re-
sulted in changes in cellular structure, with associated
decreases in cell migration, invasion, and anchorage-
dependent survival, without affecting cellular prolifera-
tion. Cells containing the PC-3M KFMSS deletion muta-
tion, however, failed to exhibit these features, and their
capacity for cell invasion was similar to that of control
cells. Our findings are similar to metastatic melanoma cell
line C8161.9 KFM and C8161.9 KFMSS cells, whereby
KFM-transfected but not KFMSS-transfected cells were
suppressed for metastasis to lung, eye, kidney, and
bone.9 These facts, coupled with the correlation of
decreased KISS1 expression with increasing metasta-
sis capacity in commonly used PCa cell lines, suggest
a clinical and biological role for KISS1 as a metastasis
suppressor in PCa.
KISS1 re-expression in ovarian, breast, pancreatic,
and melanoma cancer cells reduced metastases (50%
for ovarian cancers, 90% for melanomas, 50% for
breast cancer, 50% for pulmonary metastasis, and 95%
for hepatic metastasis in pancreatic cancer).14–19 This is
hypothesized to be through reestablishment of autocrine
or paracrine KISS1R signaling (see Beck and Welch14 for
review). Through KISS1R, KISS1 activates a variety of
signals, including phospholipase C, protein kinase C,
intracellular Ca2 mobilization, and the mitogen-acti-
vated protein kinase and phosphatidylinositol 3-kinase/
Akt pathways.14 The KISS1/KISS1R pair also affects sig-
naling events by interacting with other receptors, such as
the chemokine receptor, CXCR4, and the gonadotrophin-
releasing hormone receptor.28,29 These signals are se-
lectively triggered by kisspeptin by KISS1R in a manner
dependent on the cell type. Our data indicated that ef-
fects of KISS1 expression were not likely to be regulated
through KISS1R, because PC-3M before and after trans-
fection with KFM express low levels of receptors (Wang et
al, 2012, unpublished observation). Similarly, this has
been observed in most cell lines in which KISS1 sup-
presses metastasis,9 suggesting an alternative mecha-nism, such as an intracrine or a paracrine signaling
mechanism, or the existence of other unidentified KISS1
receptors. A recent report of plasma kisspeptin levels in
PCa suggest that circulating levels of kisspeptin are not
elevated in patients with prostatic carcinoma,30 although
KISS1R was not measured. It deserves mention that
plasma levels in this study were compared with patients
with other malignancies. Because loss of KISS1 has
been found in numerous cancer types, a comparison
from normal healthy persons should be conducted be-
fore conclusions are drawn. More investigation in this
area is warranted to determine the mechanisms by
which KISS1 functions in PCa.
Kisspeptins are thought to work through the hypo-
thalamus-pituitary-gonadal axis, which is the current
target of multiple hormone suppressive therapies.31
Although it is not clear whether KISS1 regulates go-
nadotropin-releasing hormone receptors or vise-versa,
a recent report in breast cancer reported that KISS1
and GPR54 are estrogen regulated, and their expres-
sion levels depend on the status of estrogen receptor
.23,32 A similar study that correlates KISS1 expression in
relation to androgen receptor status should be con-
ducted to further define a clinical role for KISS1 expres-
sion in PCa.
Mimetics of kisspeptin have been proposed for clinical
administration.14,33 The observation that re-expression of
KISS1 increases sensitivity to proliferation-targeting
agents such as paclitaxel provides a rationale for the
clinical use of kisspeptins or small molecules having the
properties of KISS1. These results are consistent with
the re-expression of KISS1 in head and neck squamous
cell carcinoma chemo-resistant cells, restoring chemo-
sensitivity through nuclear factor-B-associated poly
(ADP-ribose) polymerase-1 cleavage.34 Nuclear factor
B signaling in PCa is implicated in regulation of various
genes responsible for cell proliferation, epithelial to mes-
enchymal transition-associated metastasis, and resis-
tance to chemotherapy.35 Because decreased chemo-
sensitivity is associated with cancer progression to
metastasis, reversion of these cellular processes should
enhance chemosensitivity.
In conclusion, this study suggests that loss of KISS1
and KISS1R expression is associated with clinical pro-
gression of PCas. Re-expressed KISS1 exhibits proper-
ties of metastasis suppressors, that is, suppression of cell
migration and invasion and increasing cell sensitization
to anoikis and chemotherapeutic drugs. Thus, these find-
ings suggest KISS1 functions as a metastasis suppressor
in PCas and will be useful for the diagnosis, risk assess-
ment of PCa progression, and a therapeutic target for
aggressive PCas.
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